Details

Title

Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes — a minireview

Journal title

Folia Medica Cracoviensia

Yearbook

2020

Volume

Vol. 60

Numer

No 4

Affiliation

Wieczorek-Surdacka, Ewa : Chair and Department of Nephrology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland ; Surdacki, Andrzej : Second Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland ; Świerszcz, Jolanta : Department of Medical Education, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland ; Chyrchel, Bernadeta : Second Department of Cardiology, Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland

Authors

Keywords

sodium-glucose cotransporter-2 inhibitors ; glucagon-like peptide-1 receptor agonists ; renoprotection ; diabetic kidney disease ; type 2 diabetes ; cardiovascular outcome trials ; clinical practice guidelines

Divisions of PAS

Nauki Medyczne

Coverage

97-101

Bibliography

1. American Diabetes Association: Microvascular complications and foot care: Standards of Medical Care in Diabetes-2021. Standards of Medical Care in Diabetes–2020. Diabetes Care. 2020; 43 (Suppl 1): S135–S151.
2. American Diabetes Association: Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43 (Suppl 1): S98–S110.
3. American Diabetes Association: Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021; 44 (Suppl 1): S111–S124.
4. Williams D.M., Nawaz A., Evans M.: Renal outcomes in type 2 diabetes: A review of cardiovascular and renal outcome trials. Diabetes Ther. 2020; 11: 369–386.
5. Heerspink H.J.L., Stefánsson, B.V., Correa-Rotter, et al.: Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436–1446.
6. Jhund P.S., Solomon S.D., Docherty K.F., et al.: Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: Results of DAPA-HF. Circulation 2020 Oct 12; doi: 10.1161/CIRCULATIONAHA.120.050391.
7. Packer M., Anker S.D., Butler J., et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413–1424.
8. American Diabetes Association: Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019; 42 (Suppl 1): S90–S102.
9. Diabetes Poland (Polish Diabetes Association): 2020 Guidelines on the management of diabetic patients: A position of Diabetes Poland. Clin Diabetol. 2020; 9: 1–101.
10. Cosentino F., Grant P.J., Aboyans V., et al.: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41: 255–323.

Date

2021.04.08

Type

Article

Identifier

DOI: 10.24425/fmc.2020.136207

Source

Folia Medica Cracoviensia; 2020; Vol. 60; No 4; 97-101
×